FAQ

The iMOST platform is manufactured in Shanghai, China, within ISO 13485–certified facilities. These sites have successfully undergone rigorous audits by global IVD partners.

No. Cloud connectivity is optional. All analysis is performed locally on the device.

Participation in external QC programs needs to be evaluated. Please note that traditional QC materials may not always be compatible with the system due to unique differences in measurement principles.

The iMOST platform is not yet cleared or waived by the FDA. U.S. FDA 510(k) and CLIA waiver submissions are currently in preparation.

Subject to development progress, regulatory approvals, and market priorities, the following expansions are currently planned for the iMOST platform:

  • Urine Analysis: Sediment cell analysis and ACR (Albumin-to-Creatinine Ratio)
  • Blood Analysis: CRP (via docking station), CD-4 test
  • Chemistry panels: kidney, liver, lipid),
  • Immunoassay and molecular tests
Troubleshooting is typically initiated remotely. If hardware service is necessary, support is coordinated through the local distributor or an authorized service partner, adhering to the established service agreement.

N/A in certain parameter in “Results”

Possible Cause:

Certain parameters are rejected due to improper sample, improper card, or defects on the card.

Action Required:

Use a new Q-Card, repeat the measurement.

Coming Soon...